ReviewTherapeutic advances in urology2015
Management of carcinoma in situ of the bladder: best practice and recent developments.
Review in Therapeutic advances in urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.JU open plus · 2026Article
- Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Urothelial carcinoma in situ of the entire urinary tract with invasion into seminal vesicle: A case report.Urology case reports · 2025Article
- Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.BJU international · 2025Article
- Metastasis development in non-muscle-invasive bladder cancer.Nature reviews. Urology · 2025Review
- Prognostic determinants in cancer survival: a multidimensional evaluation of clinical and genetic factors across 10 cancer types in the participants of Genomics England's 100,000 Genomes Project.Discover oncology · 2024Article
- Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024Review
- Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.Cancers · 2024Article
- Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.Journal of health economics and outcomes research · 2024Article
- BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies.Frontiers in neuroscience · 2023Review
- Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?Arab journal of urology · 2023Article
- Detection of Urinary Molecular Marker Test in Urothelial Cell Carcinoma: A Review of Methods and Accuracy.Diagnostics (Basel, Switzerland) · 2022Review
- New bladder cancer non-invasive surveillance method based on voltammetric electronic tongue measurement of urine.iScience · 2022Article
- Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.International journal of molecular sciences · 2022Review
- Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer.Virchows Archiv : an international journal of pathology · 2022Article
- A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.European urology open science · 2022Article
- Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.International journal of molecular sciences · 2022Article
- Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.Virchows Archiv : an international journal of pathology · 2021Article
- Approaches to Non-Muscle-Invasive Bladder Cancer.Current oncology reports · 2021Review
- Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.Investigative and clinical urology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of carcinoma in situ of the bladder remains a complex and challenging endeavor due to its high rate of recurrence and progression. Although it is typically grouped with other nonmuscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity. Intravesical bacillus Calmette-Guérin is the standard first-line treatment given its superiority to other agents. However, high rates of bacillus Calmette-Guérin failure highlight the need for additional therapies. Radical cystectomy has traditional been the standard second-line therapy, but additional intravesical therapies may be more appealing for non-surgical candidates and patients refusing cystectomy. The subject of this review is the treatment strategies and available therapies currently available for carcinoma in situ of the bladder. It discusses alternative intravesical treatment options for patients whose condition has failed to respond to bacillus Calmette-Guérin therapy and who are unfit or unwilling to undergo cystectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.